Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Kynamro's MOA and Safety

MAY 27, 2014
James Radke


In this exclusive interview with Rare Disease Report, Sheryl Selvey, associate director of Global Medical Affairs for Kynamro at Genzyme explains the pharmacokinetic properties of Kynamro (mipomersen) and how those properties limit its drug-drug interactions as well as preventing it from entering the brain or placenta.

Henry S, Kim T-W, Geary R, et al. Lack of fetal harm and absence of drug-drug interactions attributed to unique pharmacokinetic properties of Mipomersen. Poster 139 presented at National Lipid Association Scientific Session; Orlando FL; May 1-4, 2014.

Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.